Skip to main content
Journal cover image

Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?

Publication ,  Journal Article
Fader, AN; Bergstrom, J; Jernigan, A; Tanner, EJ; Roche, KL; Stone, RL; Levinson, KL; Ricci, S; Wethingon, S; Wang, T-L; Shih, I-M; Yang, B ...
Published in: Gynecol Oncol
October 2017

OBJECTIVES: Women with advanced-stage, low-grade serous ovarian carcinoma (LGSC) have low chemotherapy response rates and poor overall survival. Most LGSC tumors overexpress hormone receptors, which represent a potential treatment target. Our study objective was to determine the outcomes of patients with advanced-stage LGSC treated with primary cytoreductive surgery (CRS) and hormone therapy (HT). METHODS: A retrospective study was performed at two academic cancer centers. Patients with Stage II-IV LGSC underwent either primary or interval CRS followed by adjuvant HT between 2004 and 2016. Gynecologic pathologists reviewed all cases. Two-year progression-free (PFS) and overall survival (OS) were calculated. RESULTS: Twenty-seven patients were studied; primary CRS followed by HT were administered in 26, while 1 patient had neoadjuvant chemotherapy followed by CRS and HT. The median patient age was 47.5, and patients had Stage II (n=2), Stage IIIA (n=6), Stage IIIC (n=18), and Stage IV (n=1) disease. Optimal cytoreduction to no gross residual was achieved in 85.2%. Ninety six percent of tumors expressed estrogen receptors, while only 32% expressed progesterone receptors. Letrozole was administered post operatively in 55.5% cases, anastrozole in 37.1% and tamoxifen in 7.4%. After a median follow up of 41months, only 6 patients (22.2%) have developed a tumor recurrence and two patients have died of disease. Median PFS and OS have not yet been reached, but 2-year PFS and OS were 82.8% and 96.3%, respectively, and 3-year PFS and OS were 79.0% and 92.6%, respectively. CONCLUSIONS: Our series describes the initial experience with cytoreductive surgery and hormonal monotherapy for women with Stage II-IV primary ovarian LGSC. While surgery remains the mainstay of treatment, chemotherapy may not be necessary in patients with advanced-stage disease who receive adjuvant hormonal therapy. A cooperative group, Phase III trial is planned to define the optimal therapy for women with this ovarian carcinoma subtype.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

October 2017

Volume

147

Issue

1

Start / End Page

85 / 91

Location

United States

Related Subject Headings

  • Triazoles
  • Tamoxifen
  • Survival Analysis
  • Retrospective Studies
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Nitriles
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Medical Overuse
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Fader, A. N., Bergstrom, J., Jernigan, A., Tanner, E. J., Roche, K. L., Stone, R. L., … Rose, P. G. (2017). Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? Gynecol Oncol, 147(1), 85–91. https://doi.org/10.1016/j.ygyno.2017.07.127
Fader, Amanda N., Jennifer Bergstrom, Amelia Jernigan, Edward J. Tanner, Kara Long Roche, Rebecca L. Stone, Kimberly L. Levinson, et al. “Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?Gynecol Oncol 147, no. 1 (October 2017): 85–91. https://doi.org/10.1016/j.ygyno.2017.07.127.
Fader, Amanda N., et al. “Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?Gynecol Oncol, vol. 147, no. 1, Oct. 2017, pp. 85–91. Pubmed, doi:10.1016/j.ygyno.2017.07.127.
Fader AN, Bergstrom J, Jernigan A, Tanner EJ, Roche KL, Stone RL, Levinson KL, Ricci S, Wethingon S, Wang T-L, Shih I-M, Yang B, Zhang G, Armstrong DK, Gaillard S, Michener C, DeBernardo R, Rose PG. Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? Gynecol Oncol. 2017 Oct;147(1):85–91.
Journal cover image

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

October 2017

Volume

147

Issue

1

Start / End Page

85 / 91

Location

United States

Related Subject Headings

  • Triazoles
  • Tamoxifen
  • Survival Analysis
  • Retrospective Studies
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Nitriles
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Medical Overuse